- Senest opdateret: Søndag, 23. februar 2020 09:30
- Publiceret: Søndag, 23. februar 2020 09:29
Det er overraskende, at man i en videnskabelig leder anno 2020 kan læse Martin Balslev Jørgensen (MBJ) argumentere for brug af benzodiazepiner udover fire uger hos patienter med depression og samtidige angstsymptomer.
MBJ refererer selv til et opdateret Cochranerewiev om emnet, der konkluderer, at der kun er veldokumenteret effekt af supplement med benzodiazepin (BZD) de første fire uger af behandlingen.
MBJ argumenterer herefter for længerevarende behandling med BZD, da det efter hans opfattelse er en klinisk erfaring, at komorbid angst og imsomni ikke ophører efter fire ugers behandling, og at andre studier har vist fortsat anxiolytisk effekt af BZD efter fire ugers behandling.
Det er muligvis vanlig praksis blandt nogle psykiatere i Danmark at fortsætte behandlingen med BZD udover fire uger, men det er imod Sundhedsstyrelsens vejledninger på området.
- Senest opdateret: Lørdag, 22. februar 2020 12:14
- Publiceret: Lørdag, 22. februar 2020 12:12
In the new documentary 'How To Make Money Selling Drugs,' Em opens up about his battle with prescription pills.
Eminem rediscovered his fire — and returned to prominence — on 2010's Recovery, the album where he came clean about his addiction to prescription pills and his struggle to remain sober.
And now, in the new documentary "How To Make Money Selling Drugs", Em reveals just how deep his addiction really was ... and how close he came to losing his life as a result.
"When I took my first Vicodin, it was like this feeling of 'Ahh.' Like everything was not only mellow, but [I] didn't feel any pain," Eminem says in the film. "I don't know at what point exactly it started to be a problem. I just remember liking it more and more. People tried to tell me that I had a problem. I would say 'Get that f-----g person outta here. I can't believe they said that sh-- to me. I'm not out there shooting heroin. I'm not f-----g out there putting coke up my nose. I'm not smoking crack."
- Senest opdateret: Søndag, 23. februar 2020 09:18
- Publiceret: Søndag, 23. februar 2020 09:12
Prescription drug overdoses have become alarmingly common in the U.S., with opioid painkillers, such as Vicodin and Oxycontin, among the drugs most frequently making headlines.
New research shows another class of drugs — benzodiazepines or "benzos" — is rising in the ranks of overdose deaths, however.
Prescriptions for such drugs, which include brand names Valium, Ativan and Xanax, tripled from 1996 to 2013, but this doesn't fully account for the uptick in overdoses, which quadrupled during that time period.
Anxiety Drug Overdoses Hit Record Levels
Researchers from the Albert Einstein College of Medicine in New York used data from the Medical Expenditure Panel Survey and multiple-cause-of-death data from the U.S. Centers for Disease Control and Prevention (CDC) to describe trends in benzodiazepine prescriptions and overdose deaths.
- Senest opdateret: Søndag, 20. oktober 2019 10:56
- Publiceret: Søndag, 20. oktober 2019 10:55
There's no understating the extent of America's opioid crisis. In 2017, the same year it became a public health emergency, an estimated 1.7 million people in the US had substance abuse disorders related to prescription opioids. And this year, the National Safety Council found that the odds of dying from an accidental opioid overdose are greater than those of dying in a car crash.
But there's another prescription drug concern that experts say has grown in the shadow of the opioid epidemic: the rise in use of benzodiazepines.
Benzodiazepines, or "benzos," are a class of medication commonly prescribed to treat conditions such as anxiety and insomnia. Even if you don't recognize the term, chances are you're familiar with the brand names that fall within this category drugs such as Xanax, Ativan, Valium and Klonopin.
"It's really not 'the opioid overdose epidemic' but the 'opioid and ...' overdose epidemic," said Dr. Chinazo O. Cunningham, an internist and a professor of family and social medicine at the Albert Einstein College of Medicine.